risperidone
risperidone is a pharmaceutical drug with 295 clinical trials. Currently 6 active trials ongoing. Historical success rate of 88.4%.
Success Metrics
Based on 220 completed trials
Phase Distribution
Phase Distribution
34
Early Stage
40
Mid Stage
167
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
85.9%
220 of 256 finished
14.1%
36 ended early
6
trials recruiting
295
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Shortened LSD Intervention for Major Depressive Disorder
A Pilot Study of Adjunctive Structured Supportive Psychotherapy in Schizophrenia
Risperidone vs Cariprazine in Acute Mania
Biomarkers to Enhance Early Schizophrenia Treatment
Clinical Trials (295)
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Shortened LSD Intervention for Major Depressive Disorder
A Pilot Study of Adjunctive Structured Supportive Psychotherapy in Schizophrenia
Risperidone vs Cariprazine in Acute Mania
Biomarkers to Enhance Early Schizophrenia Treatment
An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders
Switching Medication to Treat Schizophrenia
CLOZAPINE Response in Biotype-1
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
Effect of Cognitive Behavioral Therapy on Auditory Hallucinations and NLR in Schizophrenia Patients
"Extended" (Alternate Day) Antipsychotic Dosing
Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 295